牛牛AI助理已提取核心訊息
On December 31, 2023, a Schedule 13G amendment was filed with the SEC by Intelligent Bio Solutions Inc., indicating a significant ownership stake by Lind Global Fund II LP, Lind Global Partners II LLC, and Jeff Easton. The filing, which is a regulatory requirement for parties owning more than five percent of a company's stock, shows that these entities and individual collectively hold 960,000 shares of Intelligent Bio Solutions' common stock, representing 9.9% of the company. The ownership consists of warrants to purchase common stock, but due to exercise limitations, the beneficial ownership is capped at 960,000 shares. Jeff Easton, as the managing member of Lind Global Partners II LLC and the general partner of Lind Global Fund II LP, is deemed to have sole voting and dispositive power over the shares held by Lind Global Fund II LP. The principal business office for all reporting persons is located at 444 Madison Ave, Floor 41, New York, NY 10022. The filing, dated February 13, 2024, includes a joint filing agreement among the reporting persons.
On December 31, 2023, a Schedule 13G amendment was filed with the SEC by Intelligent Bio Solutions Inc., indicating a significant ownership stake by Lind Global Fund II LP, Lind Global Partners II LLC, and Jeff Easton. The filing, which is a regulatory requirement for parties owning more than five percent of a company's stock, shows that these entities and individual collectively hold 960,000 shares of Intelligent Bio Solutions' common stock, representing 9.9% of the company. The ownership consists of warrants to purchase common stock, but due to exercise limitations, the beneficial ownership is capped at 960,000 shares. Jeff Easton, as the managing member of Lind Global Partners II LLC and the general partner of Lind Global Fund II LP, is deemed to have sole voting and dispositive power over the shares held by Lind Global Fund II LP. The principal business office for all reporting persons is located at 444 Madison Ave, Floor 41, New York, NY 10022. The filing, dated February 13, 2024, includes a joint filing agreement among the reporting persons.
2023年12月31日，Intelligent Bio Solutions Inc. 向美國證券交易委員會提交了附表13G修正案，表明Lind Global Fund II LP、Lind Global Partners II LLC和Jeff Easton擁有大量所有權。該文件是監管部門對擁有公司5％以上股票的各方的要求，顯示這些實體和個人共持有Intelligent Bio Solutions普通股的96萬股，佔該公司的9.9％。所有權包括購買普通股的認股權證，但由於行使限制，受益所有權上限爲960,000股。傑夫·伊斯頓作爲Lind Global Partners II LLC的管理成員...展開全部
2023年12月31日，Intelligent Bio Solutions Inc. 向美國證券交易委員會提交了附表13G修正案，表明Lind Global Fund II LP、Lind Global Partners II LLC和Jeff Easton擁有大量所有權。該文件是監管部門對擁有公司5％以上股票的各方的要求，顯示這些實體和個人共持有Intelligent Bio Solutions普通股的96萬股，佔該公司的9.9％。所有權包括購買普通股的認股權證，但由於行使限制，受益所有權上限爲960,000股。傑夫·伊斯頓作爲Lind Global Partners II LLC的管理成員和Lind Global Fund II LP的普通合夥人，被視爲對Lind Global Fund II LP持有的股票擁有唯一的投票權和處置權。所有申報人的主要業務辦公室位於紐約麥迪遜大道444號41樓，郵編10022。該文件日期爲2024年2月13日，包括申報人之間的聯合申報協議。
有用
沒用